AU2005235383B2 - Pharmaceutical composition comprising a salt of mirtazapine - Google Patents

Pharmaceutical composition comprising a salt of mirtazapine Download PDF

Info

Publication number
AU2005235383B2
AU2005235383B2 AU2005235383A AU2005235383A AU2005235383B2 AU 2005235383 B2 AU2005235383 B2 AU 2005235383B2 AU 2005235383 A AU2005235383 A AU 2005235383A AU 2005235383 A AU2005235383 A AU 2005235383A AU 2005235383 B2 AU2005235383 B2 AU 2005235383B2
Authority
AU
Australia
Prior art keywords
mirtazapine
salt
enantiomer
crystalline form
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2005235383A
Other languages
English (en)
Other versions
AU2005235383A1 (en
Inventor
Gerardus Johannes Kemperman
Sytske Hyke Moolenaar
Kees Van Der Voort Maarschalk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon NV
Original Assignee
Organon NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Organon NV filed Critical Organon NV
Publication of AU2005235383A1 publication Critical patent/AU2005235383A1/en
Application granted granted Critical
Publication of AU2005235383B2 publication Critical patent/AU2005235383B2/en
Assigned to MSD OSS B.V. reassignment MSD OSS B.V. Request to Amend Deed and Register Assignors: N.V ORGANON
Assigned to MERCK SHARP & DOHME B.V. reassignment MERCK SHARP & DOHME B.V. Request to Amend Deed and Register Assignors: MSD OSS B.V.
Assigned to N.V. ORGANON reassignment N.V. ORGANON Request for Assignment Assignors: MERCK SHARP & DOHME B.V.
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2005235383A 2004-04-21 2005-04-19 Pharmaceutical composition comprising a salt of mirtazapine Expired AU2005235383B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04101664.3 2004-04-21
EP04101664 2004-04-21
PCT/EP2005/051714 WO2005102352A1 (en) 2004-04-21 2005-04-19 Pharmaceutical composition comprising a salt of mirtazapine

Publications (2)

Publication Number Publication Date
AU2005235383A1 AU2005235383A1 (en) 2005-11-03
AU2005235383B2 true AU2005235383B2 (en) 2010-05-27

Family

ID=34928990

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005235383A Expired AU2005235383B2 (en) 2004-04-21 2005-04-19 Pharmaceutical composition comprising a salt of mirtazapine

Country Status (31)

Country Link
US (1) US20070111993A1 (enExample)
EP (1) EP1729777B1 (enExample)
JP (2) JP5260959B2 (enExample)
CN (2) CN1942191B (enExample)
AR (1) AR049028A1 (enExample)
AT (1) ATE424210T1 (enExample)
AU (1) AU2005235383B2 (enExample)
BR (1) BRPI0509953A (enExample)
CA (1) CA2561281C (enExample)
CY (1) CY1109018T1 (enExample)
DE (1) DE602005013066D1 (enExample)
DK (1) DK1729777T3 (enExample)
EC (1) ECSP066938A (enExample)
ES (1) ES2321961T3 (enExample)
HR (1) HRP20090190T1 (enExample)
IL (1) IL178201A (enExample)
LV (1) LV13556B (enExample)
MX (1) MXPA06011830A (enExample)
MY (1) MY144899A (enExample)
NO (1) NO20065077L (enExample)
NZ (1) NZ550052A (enExample)
PE (1) PE20060400A1 (enExample)
PL (1) PL1729777T3 (enExample)
PT (1) PT1729777E (enExample)
RS (1) RS50764B (enExample)
RU (1) RU2375362C2 (enExample)
SI (1) SI1729777T1 (enExample)
TW (1) TW200538100A (enExample)
UA (1) UA89773C2 (enExample)
WO (1) WO2005102352A1 (enExample)
ZA (1) ZA200608305B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA83666C2 (ru) * 2003-07-10 2008-08-11 Н.В. Органон Способ получения энантиомерно чистого миртазапина
EP1792618A1 (en) * 2005-11-30 2007-06-06 Rainer Freynhagen R-mirtazapine for the treatment of pain
TW200808804A (en) * 2006-05-22 2008-02-16 Organon Nv Mirtazapine for the treatment of neuropathic pain
CN104095824B (zh) * 2013-04-09 2016-08-31 上海信谊万象药业股份有限公司 一种米氮平缓释片及其制备方法
JP6876003B2 (ja) 2015-02-27 2021-05-26 デクラ リミテッド イヌ及びネコにおける、食欲の刺激、体重減少の管理、及び拒食症の処置
CN111053735A (zh) * 2020-02-25 2020-04-24 上海阶平医院管理有限公司 一种治疗失眠的冷敷凝胶

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0813873A1 (en) * 1996-06-19 1997-12-29 Akzo Nobel N.V. Pharmaceutical composition comprising mirtazapine and one or more selective serotonin reuptake inhibitors
WO2001000196A2 (en) * 1999-06-25 2001-01-04 University Of South Florida Mirtazapine for weight gain in wasting diseases
WO2001019371A1 (en) * 1999-09-15 2001-03-22 Richter, Reed TREATMENT OF MOVEMENT DISORDERS BY ADMINISTRATION OF 5-HYDROXYTRYPTAMINE RECEPTOR/α2 ADRENERGIC RECEPTOR ANTAGONIST COMPOSITIONS

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL189199C (nl) * 1975-04-05 1993-02-01 Akzo Nv Werkwijze ter bereiding van farmaceutische preparaten met werking op het centraal zenuwstelsel op basis van benz(aryl)azepinederivaten, de verkregen gevormde farmaceutische preparaten, alsmede werkwijze ter bereiding van de toe te passen benz(aryl)azepinederivaten.
US4193828A (en) * 1976-07-27 1980-03-18 Fiber Materials, Inc. Method of forming carbon composites
US4515792A (en) * 1982-09-30 1985-05-07 Ciba-Geigy Corporation Tetracyclic heterocycles and antidepressant compositions thereof
IL121076A (en) * 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
ES2212550T3 (es) * 1998-04-02 2004-07-16 Akzo Nobel N.V. Solucion oral liquida que comprende el antidepresor mirtazapina.
WO2001042239A1 (en) * 1999-12-13 2001-06-14 Sumika Fine Chemicals Co., Ltd. Process for the preparation of a pyridinemethanol compound
HK1047547B (en) * 2000-04-05 2003-10-10 Akzo Nobel N.V. Drug combination for the treatment of headache comprising mirtazapine and paracetamol or a non-steroidal anti-inflammatory drug

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0813873A1 (en) * 1996-06-19 1997-12-29 Akzo Nobel N.V. Pharmaceutical composition comprising mirtazapine and one or more selective serotonin reuptake inhibitors
WO2001000196A2 (en) * 1999-06-25 2001-01-04 University Of South Florida Mirtazapine for weight gain in wasting diseases
WO2001019371A1 (en) * 1999-09-15 2001-03-22 Richter, Reed TREATMENT OF MOVEMENT DISORDERS BY ADMINISTRATION OF 5-HYDROXYTRYPTAMINE RECEPTOR/α2 ADRENERGIC RECEPTOR ANTAGONIST COMPOSITIONS

Also Published As

Publication number Publication date
JP2007533705A (ja) 2007-11-22
BRPI0509953A (pt) 2007-09-25
US20070111993A1 (en) 2007-05-17
AU2005235383A1 (en) 2005-11-03
ECSP066938A (es) 2006-12-20
DK1729777T3 (da) 2009-06-08
PE20060400A1 (es) 2006-05-27
IL178201A0 (en) 2006-12-31
ATE424210T1 (de) 2009-03-15
NZ550052A (en) 2010-02-26
PT1729777E (pt) 2009-04-27
SI1729777T1 (sl) 2009-08-31
RU2006140988A (ru) 2008-05-27
EP1729777A1 (en) 2006-12-13
RS50764B (sr) 2010-08-31
CN101824035A (zh) 2010-09-08
CN1942191A (zh) 2007-04-04
EP1729777B1 (en) 2009-03-04
CN1942191B (zh) 2011-02-02
MXPA06011830A (es) 2007-03-23
RU2375362C2 (ru) 2009-12-10
JP2013136626A (ja) 2013-07-11
DE602005013066D1 (de) 2009-04-16
WO2005102352A1 (en) 2005-11-03
UA89773C2 (ru) 2010-03-10
CA2561281C (en) 2013-04-02
MY144899A (en) 2011-11-30
ZA200608305B (en) 2008-08-27
IL178201A (en) 2010-06-30
AR049028A1 (es) 2006-06-21
JP5260959B2 (ja) 2013-08-14
LV13556B (en) 2007-07-20
NO20065077L (no) 2006-11-14
CY1109018T1 (el) 2014-07-02
PL1729777T3 (pl) 2009-07-31
CA2561281A1 (en) 2005-11-03
TW200538100A (en) 2005-12-01
ES2321961T3 (es) 2009-06-15
HRP20090190T1 (en) 2009-05-31

Similar Documents

Publication Publication Date Title
EP2112155B1 (en) Hydrogensulfate salt of 2-acetoxy-5-(a-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine and its preparation
KR100896266B1 (ko) 네비볼올 및 그의 약학적으로 허용되는 염, 네비볼올의제조방법 및 네비볼올의 약학적 조성물
TW200303303A (en) Novel pyridine-and quinoline-derivatives
JP2008534470A (ja) Ｄｐｐ−ｉｖ阻害剤の新規な塩及び多形
JP2013136626A (ja) ミルタザピンの塩を含む医薬組成物
AU2011213936A1 (en) Process for the preparation of alpha form of imatinib mesylate
JP2023517729A (ja) Ｔａａｒ１アゴニストの塩形態および結晶形態
US7470707B2 (en) Crystalline monohydrate clopidogrel naphthalenedisulfonate and process of preparation
HRP20090470A2 (hr) Sol 3-benzil-2-methil-2.3.3.a.4.5.6.7,7a-octahidrobenzo[d]isoksazol-4-ona
EP3592734B1 (en) Amine salt of (1r,3s)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentane carboxylic acid
WO2019134455A1 (zh) Acalabrutinib的新晶型及其制备方法和用途
DK169622B1 (da) Trans-(+)-stereoisomere af pyrimido[4,5-g]quinolin-derivater eller farmaceutisk acceptable syreadditionssalte deraf samt farmaceutiske formuleringer indeholdende sådanne forbindelser
KR20070022037A (ko) 미르타자핀의 염을 포함하는 약학 조성물
WO2012123958A1 (en) Highly pure salts of clopidogrel free of genotoxic impurities
JP2022511979A (ja) Ｓｃｙ－６３５のマレイン酸塩、及び医学におけるその使用
US20060094764A1 (en) Cyanothiophenes, their preparation and their use in pharmaceutical compositions
JP2002030080A (ja) （３ｓ−トランス）−２−［３，４−ジヒドロ−４−ヒドロキシ−３−（フェニルメチル）−２ｈ−１−ベンゾピラン−７−イル］−４−（トリフルオロメチル）−安息香酸の新規結晶形体
TW202506661A (zh) 一種酪氨酸激酶抑制劑的可藥用鹽、結晶形式及其製備方法
HK40020652B (en) Amine salt of (1r,3s)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl) cyclopentane carboxylic acid
HK40020652A (en) Amine salt of (1r,3s)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl) cyclopentane carboxylic acid
WO2019011336A1 (zh) Qaw-039的晶型及其制备方法和用途
JPWO2006121104A1 (ja) ピペリジン環を有するインドール誘導体の結晶およびその製法

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: N.V. ORGANON

Free format text: FORMER OWNER(S): MERCK SHARP & DOHME B.V.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired